newsfilter
← Latest News
GlobeNewswire·

Compass Therapeutics Reports 2026 Third Quarter Financial Results and Provides Corporate Update

Compass is advancing preparations for a BLA submission for tovecimig in patients with BTC and plans to further engage with the FDA.Data from the COMPANION-002 study of tovecimig, including newly disclosed durability of